Pharma R&D partnerships are on the rise: report

Drugmakers are increasingly collaborating with technology companies, medical associations, health systems, and other life-sciences companies in an attempt to better deal with a challenging drug-development environment.

There were 4,000 R&D partnerships between biopharmaceutical companies and other stakeholders, between 1995 and 2004, according to a recent report from Deloitte that was funded by PhRMA. In the decade after, the number of partnerships doubled to 9,000. Early stage partnerships, defined as those formed prior to a therapy entering clinical trials, also doubled: growing from 256 in 2005 to 578 in 2014.

See also: Pharma is reluctant to adopt digital in R&D: survey

Neil Lesser, a principal with Deloitte Consulting, said that drug research is more challenging now due to three factors: the complexity of specialty drugs, the emphasis on new sources of data, such as patient-reported outcomes and real-world evidence; and the attention paid by  health plans and providers to a medicine's value.

Of the 45 novel drugs approved by the FDA in 2016, 46% were for rare or orphan diseases; 36% were first-in-class medicines; and 25% were personalized treatments, according to Lesser.

See also: Pharma companies turn to wearables to improve R&D

Interestingly, the report forecast that non-asset partnerships — collaborations designed to advance research that is not centered around a particular product or compound — are also growing. The number of these partnerships, which are sometimes referred to as joint ventures and consortia, went from 34 in 2005 to 334 in 2014.


Next Article in Data/Analytics